Recent studies focused on 12 CSF sphingomyelin metabolites (SM) (Morrow et al., 2021) or derived principal components from 308 CSF metabolites (Dong et al., 2022) also suggested evidence of an association between CSF metabolites and AD biomarkers, e.g., SM (d18:1/14:0, d16:1/16:0) and p-tau, NFL, and α -synuclein. The gene discussed is MAPT; the disease is Alzheimer disease.